# Reirradiation and Erbitux in the HNSCC

> **NCT01237483** · PHASE2 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 50 (actual)

## Conditions studied

- Head and Neck Cancer Squamous Cell

## Interventions

- **DRUG:** Erbitux

## Key facts

- **NCT ID:** NCT01237483
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2016-07
- **Final completion:** 2016-07-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237483, "Reirradiation and Erbitux in the HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01237483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*